D-0508-2023 Class II Ongoing
FDA drug recall D-0508-2023 was initiated by Direct Rx on Mar 22, 2023 and is designated Class II. Reason for recall: CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer. The recall status is ongoing. Affected quantity: 349 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 12, 2023
- Initiation Date
- Mar 22, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 349 bottles
Product description
Alprazolam C-IV, 1 mg, packaged in a) 30 Tabs per bottle, NDC 72189-213-30; b) 60 Tabs per bottle, NDC 72189-213-60; Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534.
Reason for recall
CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.
Distribution pattern
Nationwide in the USA
Code information
Lots: a) 03FE2318, Exp. 8/31/24; b) 27FE2315, 28FE2313, 02MA2306, 21SE2201, 16NO2216, 17NO2216, 24FA2314, Exp. 8/31/24; 17FE2203, 12AP2204, 17MA2205, Exp. 3/31/23; 21JU2206, 22JU2220, 12JY2206, Exp. 5/31/23; 10AU2209, Exp. 6/30/23; 14DE2215, Exp. 9/30/24; 05JA2304, 27JA2301, Exp. 11/30/24.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0508-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026